ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as EVP, Head of Research and Development

ACADIA Pharmaceuticals Inc.

, a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development. With a background in clinical and academic psychiatry, Dr. Stankovic brings over 20 years of executive level experience in drug development and clinical and medical affairs. "I am delighted to welcome Serge to our team," said Steve Davis, ACADIA's President and Chief Executive Officer. "Serge has a track record of transforming promising research into important medicines that address unmet needs of patients. We look forward to his contributions as we advance NUPLAZID™ through NDA review for Parkinson's disease psychosis, prepare for the planned commercialization of NUPLAZID in the United States and continue our efforts to explore the full potential of NUPLAZID to treat patients suffering from additional CNS disorders." "There is a strong need for continued innovation in the treatment of CNS disorders such as Parkinson's disease, Alzheimer's disease, and schizophrenia," said Dr. Stankovic. "ACADIA is at the forefront in developing groundbreaking medicines to treat debilitating symptoms associated with these diseases. I look forward to leading the team in advancing the promising development programs with NUPLAZID." Dr. Stankovic has built and led multidisciplinary teams for small molecules and biologics in therapeutic areas including neurology, psychiatry, oncology, cardiology and pain. He has led teams to achieve approvals of KEPPRA®, FENTORA®, TREANDA®, NUVIGIL® and ARISTADA™. Dr. Stankovic most recently served as Senior Vice President of Clinical Development and Medical Affairs at Alkermes plc. from 2013 to 2015. Prior to Alkermes, he held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals Ltd. He was appointed to this role following Teva's acquisition of Cephalon, Inc. where he served as Senior Vice President, Worldwide Clinical Research. Dr. Stankovic also held executive positions in research and development at Forest Laboratories, Inc., Neurogen Corporation, Johnson and Johnson, and UCB. Dr. Stankovic received his M.D. from the University of Belgrade and holds a Master of Science in Public Health from the University of Alabama at Birmingham.